F. Barlesi, J. Mazieres, and J. P. Merlio, Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT), Lancet, vol.387, pp.1415-1426, 2016.

A. T. Shaw, S. H. Ou, and Y. J. Bang, Crizotinib in ROS1-rearranged non-small-cell lung cancer, N Engl J Med, vol.371, pp.1963-1971, 2014.

D. R. Camidge, Y. J. Bang, and Y. L. Kwak, Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study, Lancet Oncol, vol.13, pp.1011-1019, 2012.

A. T. Shaw, D. W. Kim, and K. Nakagawa, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med, vol.368, pp.2385-2394, 2013.

B. J. Solomon, T. Mok, and D. W. Kim, First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N Engl J Med, vol.371, pp.2167-2177, 2014.

R. Katayama, A. T. Shaw, and T. M. Khan, Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers, Sci Transl Med, vol.4, pp.120-137, 2012.

S. H. Ou, P. A. Jänne, and C. H. Bartlett, Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC, Ann Oncol, vol.25, pp.415-422, 2014.

A. J. Weickhardt, B. Scheier, and J. M. Burke, Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer, J Thorac Oncol, vol.7, pp.1807-1814, 2012.

L. Friboulet, N. Li, and R. Katayama, The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer, Cancer Discov, vol.4, pp.662-663, 2014.
DOI : 10.1158/2159-8290.cd-13-0846

URL : http://cancerdiscovery.aacrjournals.org/content/candisc/4/6/662.full.pdf

, FDA broadens ceritinib indication to previously untreated ALK-positive metastatic NSCLC, US Food and Drug Administration

A. T. Shaw, D. W. Kim, and R. Mehra, Ceritinib in ALK-rearranged non-small-cell lung cancer, N Engl J Med, vol.370, pp.1189-1197, 2014.

D. W. Kim, R. Mehra, and D. S. Tan, Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial, Lancet Oncol, vol.17, pp.452-463, 2016.

E. Felip, S. Orlov, and K. Park, Phase 2 study of ceritinib in ALKi-naïve patients ( pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): whole body responses in the overall pt group and in pts with baseline brain metastases (BM), Ann Oncol, vol.27, 2016.

L. Crinò, M. J. Ahn, D. Marinis, and F. , Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2, J Clin Oncol, vol.34, pp.2866-2873, 2016.

J. C. Soria, D. S. Tan, and R. Chiari, First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study, Lancet, vol.389, pp.917-929, 2017.

A. T. Shaw, T. M. Kim, and L. Crinò, ASCEND-5: a randomised, phase 3 study of ceritinib versus chemotherapy in adult patients with ALK-rearranged non-small cell lung cancer, previously treated with chemotherapy and crizotinib, Lancet Oncol, vol.18, pp.874-886, 2017.

J. Cohen, L. Faden, and S. Predaris, Patient access to pharmaceuticals: an international comparison, Eur J Health Econ, vol.8, pp.253-266, 2007.

A. Degrassat-théas, P. Paubel, and O. Parent-de-curzon, Temporary authorization for use: does the French patient access programme for unlicensed medicines impact market access after formal licensing?, Pharmacoeconomics, vol.31, pp.335-343, 2013.

J. Cadranel, K. Park, and O. Arrieta, Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study, Lung Cancer, vol.98, pp.9-14, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01314916

J. F. Gainor, D. S. Tan, D. Pas, and T. , Progression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and ceritinib, Clin Cancer Res, vol.21, pp.2745-2752, 2015.

S. Lantuejoul, I. Rouquette, and H. Blons, French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas, Eur Respir J, vol.46, pp.207-218, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01679639

A. Mcleer-florin, D. Moro-sibilot, and A. Melis, Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study, J Thorac Oncol, vol.7, pp.348-354, 2012.

B. Besse, A. Adjei, and P. Baas, 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease, Ann Oncol, vol.25, pp.1475-1484, 2014.

P. A. Tang, G. R. Pond, and E. X. Chen, Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials, Ann Oncol, vol.21, pp.19-26, 2010.

M. Duruisseaux, M. Leer-florin, A. Moro-sibilot, and D. , Are all ALK rearrangements created equal?, Transl Cancer Res, vol.6, pp.585-586, 2017.

B. C. Cho, D. Kim, and A. Bearz, ASCEND-8: a randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC), J Thorac Oncol, vol.12, pp.1357-1367, 2017.